Navigation Links
Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
Date:3/8/2012

d in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel medicines and solutions in five distinct therapeutic areas: Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research & Development, LLC visit www.janssenrnd.com.

Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.  Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to address serious unmet medical needs around the world.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the hea
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Dec. 9, 2010 Customers using Elekta,s ... with seamless integration to Varian,s TrueBeam ™ ... to this linear accelerator is the most recent ... and the delivery systems of other cancer management ...
... Conn., Dec. 9, 2010 Boehringer Ingelheim Pharmaceuticals, Inc. ... the phase IIb/III LUX-Lung 1 trial show that afatinib ... 1.0 month for placebo) in progression-free survival (PFS) in ... to have an epidermal growth factor receptor (EGFR) mutation.(1) ...
Cached Medicine Technology:Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 2Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 2New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 4New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 5
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... recall as number of people sickened in outbreak rises to ... Jan. 14 (HealthDay News) -- A nationwide recall of peanut ... even as the number of people sickened by salmonella-contaminated peanut ... of America, based in Lynchburg, Va., issued the recall of ...
... effort by national SEIU officials to oust reformers, ... United Healthcare Workers (UHW) President Sal Rosselli and ... afternoon, according to UHW election committee chair Debby ... by national SEIU President Andy Stern to oust ...
... had fewer problems and a much higher quality of life ... three weeks after being discharged from hospital, according to research ... Nursing . , During the two-year study, researchers from Umea ... pedestrians who had attended the same emergency department after an ...
... Obesity continues to increase for women in the United ... ages of 35-44, there are approximately 3.3 million white ... who are obese. A new study published in the ... is an increased risk for midlife obesity among Mexican-American ...
... study from Indiana University suggests that even meager levels ... with serious mental illnesses (SMI) such as bipolar disorder, ... in the November issue of the " International Journal ... people with SMI demonstrate low levels of physical activity ...
... Jan. 14 Genworth Financial,s Long Term Care (LTC) ... the National LTC Network to sell Genworth,s long term ... National LTC Network will offer Genworth,s long term care ... will help expand Genworth,s distribution of its long term ...
Cached Medicine News:Health News:More Peanut Butter Recalled in Salmonella Outbreak 2Health News:More Peanut Butter Recalled in Salmonella Outbreak 3Health News:United Healthcare Workers Re-Elect All Statewide Officers 2Health News:Telephone support after traffic accidents reduces problems and improves quality of life 2Health News:Telephone support after traffic accidents reduces problems and improves quality of life 3Health News:Economic status affects obesity rates in Mexican-American and white women 2Health News:Physical activity, mood and serious mental illness 2Health News:Genworth Forges Strategic Relationship with National LTC Network 2
CCR Medical conventional laryngoscopes....
... Original LMA™ Airway., ,Launched in 1988, ... use is now standard practice in general ... worldwide the LMA Classic™ is a safe ... ,The LMA Classic™ can be used ...
... , ,Developed for cardiopulmonary resuscitation and ... LMA Fastrach™ has been designed to facilitate ... neck. The LMA Fastrach™ allows continuous ventilation ... emergency teams worldwide including NASA for its ...
... the production of airway management ... integrated solution to all your ... Portex Soft Seal Laryngeal Mask ... this wide portfolio of products ...
Medicine Products: